Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts

Group Heralds Semaglutide’s Positive Phase II NASH Outcome

 
• By Sten Stovall
Novo_Nordisk
GLP-1 semaglutide met its primary endpoint in the Phase II proof-of-concept study • Source: Shutterstock

More from Clinical Trials

More from R&D